Review of conditioning regimens for haplo-identical donor transplants using post-transplant cyclophosphamide in recipients of G-CSF mobilised peripheral stem cell

Haplo-identical transplant activity has significantly increased recently, with highest increase seen in South East Asia/West Pacific region (48.6%), followed by Europe (29.9%) and the Americas (19.8%)1 . The most common platforms to overcome HLA-mismatching are: 1) Anti-thymocytic globulin (ATG)-based and 2) Post-transplant cyclophosphamide-based (PTCy). The ATG-based platform is used extensively in China and involves use of G-CSF mobilised peripheral stem cells as well as G-CSF primed bone marrow.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Hot Topic Source Type: research